NCT07634536
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
Not Yet Recruiting
PHASE2Ages 18–70InterventionalTreatmentStanford UniversityInvestigator-initiated
~30 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI)FludarabineCyclophosphamideAllogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)Mycophenolate mofetil (MMF)Tacrolimus
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Non-Relapse Mortality (NRM)
Measured over Day 100 after transplantation
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Hany Elmariah, MD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age 18 to 60 years (inclusive)
HCT Co-Morbidity score (HCT-CI) \< 5 (http://www.qxmd.com/calculate-online/hematology/hct-ci)(31)
Adequate performance status is defined as Karnofsky score ≥ 70%
Patients must be receiving an allogeneic peripheral blood stem cell graft
Patients and selected donor must be HLA typed at high resolution using DNA based typing at the following HLA-loci: HLA-A, -B, -C and DRB1. Donors may be an 8/8 matched sibling donor, 8/8 matched unrelated donor, haploidentical related donor, or 7/8 mismatched unrelated donor. 2. Eligible Diseases (Any one of the following)
Blasts \>5% in the peripheral blood and/or bone marrow after \>2 prior lines of AML directed therapy, present during the trial screening window
Adverse plus risk by AlloHCT Refined ELN Criteria: defined as having complex cytogenetics, TP53 mutation, or MECOM rearrangement confirmed at any time point.(32)
Blasts \>10% in the peripheral blood and/or bone marrow after \>1 prior line of therapy.
TP53 mutation confirmed at any time point
Blasts \>10% in the peripheral blood and/or bone marrow during the trial screening window
TP53 mutation confirmed at any time point 3. Adequate organ function is defined as all of the following:
What this trial measures
- Non-Relapse Mortality (NRM)Day 100 after transplantation
Death without prior disease relapse following allogeneic peripheral blood stem cell transplantation.
- Neutrophil EngraftmentThrough Day 100 after transplantation
Neutrophil engraftment following allogeneic peripheral blood stem cell transplantation.